Mortality Caused by <i>Candida auris</i> Bloodstream Infections in Comparison with Other Candida Species, a Multicentre Retrospective Cohort

<i>Candida auris</i> is an emerging pathogen considered to be critical in the World Health Organization fungal organisms list. The study aims to determine the mortality and hospital stays attributed to <i>Candida auris</i> (<i>C. auris</i>) compared to other <i>Candida</i> species in adult patients with candidemia. A retrospective cohort of adults with candidemia was examined from seven centres in Colombia between 2016 and 2021. The primary outcome was 30-day mortality, and the secondary outcome was the length of hospital stay among survivors. Adjustment of the confounding variables was performed using inverse probability weights of exposure propensity score (candidemia by <i>C. auris</i>), survival regression models (Weibull distribution), and a counting model (negative binomial distribution). A value of 244 (47.6%) of the 512 patients with candidemia died within the first 30 days. The crude mortality in <i>C. auris</i> was 38.1% vs. 51.1% in <i>Candida</i> non-auris (CNA). In the Weibull model, mortality in the <i>C. auris</i> group was lower (adjusted HR: aHR- 0.69, 95% CI: 0.53–0.90). Antifungal treatment also decreased mortality, with an aHR of 0.36 (95% CI 0.27–0.47), while the presence of septic shock on patient progression increased it, with an aHR of 1.73 (95% CI 1.41–2.13). Among the patients who survived, no differences in the length of hospital stay were observed between the <i>C. auris</i> and the CNA groups, with an incidence rate ratio of 0.92 (95% CI: 0.68–1.22). Mortality in patients with <i>C. auris</i> bloodstream infections appears lower when adjusted for numerous confounding variables regarding treatment and the presence of septic shock in patient progression. We identified no significant effect of <i>C. auris</i> on the length of hospital stay in surviving patients.